Tango plans to move the combo approach to a Phase 3 trial
National Cancer Institute/USC Norris Comprehensive Cancer Center
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients.
Its next act — this time as a co-lead — was revealed Monday.
